Byung Gyu Kim

Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR).

K. Yamaguchi, J. Nuss, J. Woolfrey, 2013, Journal of medicinal chemistry.

SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors.

J. Martini, J. Nuss, Wentao Zhang, 2012, Bioorganic & medicinal chemistry letters.

Oral proteasome inhibitor with strong preclinical efficacy in myeloma models

C. Min, Sung‐Eun Lee, K. Won, 2016, BMC Cancer.

Identification of β-Lapachone Analogs as Novel MALT1 Inhibitors To Treat an Aggressive Subtype of Diffuse Large B-Cell Lymphoma.

Sungwoo Hong, Y. Jeong, H. Tae, 2015, Journal of medicinal chemistry.

Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase γ inhibitors.

Charles R. Holst, J. Nuss, Xiang Wu, 2012, Journal of medicinal chemistry.